MediWoundMDWD +2.19%56 Gross Margin % is 21.90% as of Mar. 2026, which is 39% below its 10-year median of 35.73. GuruFocus rates MDWD with a GF Score™ of 56/100 and a GF Value™ of $12.44 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 732 Biotechnology companies, MediWound ranks worse than 84.02% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. MediWound's Gross Profit for the
three
months ended in Mar. 2026 was $0.32 Mil. MediWound's Revenue for the
three
months ended in Mar. 2026 was $1.48 Mil. Therefore, MediWound's Gross Margin % for the quarter that ended in Mar. 2026 was 21.90%.
Warning Sign:
MediWound Ltd gross margin has been in long-term decline. The average rate of decline per year is -18.2%.
The historical rank and industry rank for MediWound's Gross Margin % or its related term are showing as below:
MDWD'
s Gross Margin % Range Over the Past 10 Years
Min: -38.51 Med: 35.73 Max: 62.73
Current: 19.61
During the past 13 years, the highestGross Margin % of MediWound was 62.73%. The lowest was -38.51%. And the median was 35.73%.
MDWD's Gross Margin % is ranked worse than 84.02% of 732
companies
in the Biotechnology industry
Industry Median: 60.91
vs MDWD: 19.61
MediWound had a gross margin of 21.90% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for MediWound was -18.20% per year.
MediWound (NAS:MDWD) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
MediWound had a gross margin of 21.90% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
MediWound Gross Margin % Related Terms
MediWound Gross Margin % Historical Data
* Premium members only.
The historical data trend for MediWound's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDWD vs UNCY, ARCT, NGEN: Gross Margin % Comparison
For the Biotechnology subindustry, MediWound's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediWound Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediWound's Gross Margin % distribution charts can be found below:
* The bar in red indicates where MediWound's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
MediWound (MDWD) has a Gross Margin % of 21.90% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on MediWound and its competitors. This is 39% below median its historical median of 35.73. According to the industry distribution chart, MediWound ranks #615 out of 732 companies in the Biotechnology industry, placing it in the top 84%.
Is MediWound's Gross Margin % too high?
MediWound's current Gross Margin % of 21.90% is 39% below median its 10-year median of 35.73. The Biotechnology industry median Gross Margin % is 60.91. MediWound's value of 21.90% is 64% below this industry median. Based on the distribution chart, MediWound ranks #615 out of 732 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's Gross Margin % compare to UNCY and ARCT?
According to the Biotechnology industry distribution chart, MediWound ranks #615 out of 732 companies for Gross Margin %. This places MediWound in the lower half of its industry. The industry median Gross Margin % is 60.91. MediWound's value of 21.90% is 64% below this benchmark. While the company's 10-year median is 35.73 vs. the industry median of 60.91, MediWound has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediWound's current Gross Margin % of 21.90% is 64% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on MediWound and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediWound's current Gross Margin % is 21.90%, which is 39% below median its own 10-year median of 35.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.44, compared to a current price of $15.16 — trading 21.9% above its estimated fair value. The current Gross Margin % is 21.90%, which is 39% below median its 10-year median of 35.73 and 64% below the Biotechnology industry median of 60.91. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For MediWound (MDWD), the current Gross Margin % is 21.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediWound (MDWD) Overvalued in 2026?
Based on GuruFocus' analysis, MediWound stock appears to be overvalued.
The current stock price of $15.16 is trading 21.9% above its estimated GF Value™ of $12.44.
GuruFocus considers MediWound to be Modestly Overvalued.
Key valuation signals for MDWD:
Gross Margin %: 21.90% (39% below median its 10-year median of 35.73)
GF Value™: $12.44 vs. price of $15.16 (21.9% above fair value)
Industry Position: 64% below the Biotechnology median (#615 of 732)
No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score
Get the complete analysis for MDWD
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDWD has been successfully added to your 
